‹ ›

This content requires a premium subscription.
Please log in or subscribe to continue.
Artwork for ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
ESC Cardio Talk

ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
30
00:00:00 / 00:09:47